Literature DB >> 11206835

Isolation and characterization of cell lines with reduced urokinase binding.

H K Lau1, J M Teitel, M Kim.   

Abstract

Six cell lines have been generated from the human fibrosarcoma HT-1080 by mutagenesis. They were selected on the basis of reduced urokinase (uPA) binding on replicate polyester filters. Single cell clones were then isolated by limited dilution cloning. All cloned cells showed less uPA binding on filters, and as cell monolayers. These cell lines were able to bind only 10 to 65% as much uPA as the wild-type HT-1080 cells. Surface-bound uPA proteolytic activity and surface activation of plasminogen from these cells were also reduced relative to the wild-type. uPA could activate MAP kinases in the wild-type and two of the cell lines with the least uPA-binding, but the amount of the activated forms of the signalling molecules were reduced. Immunoblotting using two different anti-uPA receptor antibodies showed two cross-reacting protein species of approximately 53 kDa and approximately 38 kDa. The proportion of the lower Mr band to the higher Mr band was found to be reduced in all the cell lines relative to the wild-type. Chemical cross-linking with single-chain urokinase (scuPA) showed only one high-molecular-weight adduct, with Mr approximately 90 kDa, in all the cell lines tested. Similarly, cross-linking with the amino terminal fragment of uPA yielded a single approximately 70 kDa adduct. These would indicate that only the approximately 53 kDa band was responsible for cross-linking reactions. Equilibrium binding experiments showed that only one set of high-affinity binding sites for the wild-type cells. However, the binding of scuPA to two of these cell lines was best fitted to a two-site model, one of which was similar to the high-affinity binding sites of the wild-type, although the number of sites was reduced, while the other was of much lower affinity but was large in number. These results are discussed in relation to changes in the structure of ligand binding machinery in these cells, which affect other cellular functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11206835     DOI: 10.1023/a:1026521216811

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Autocrine saturation of pro-urokinase receptors on human A431 cells.

Authors:  M P Stoppelli; C Tacchetti; M V Cubellis; A Corti; V J Hearing; G Cassani; E Appella; F Blasi
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.

Authors:  D Boyd; G Florent; P Kim; M Brattain
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

4.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.

Authors:  L A Liotta; R H Goldfarb; R Brundage; G P Siegal; V Terranova; S Garbisa
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

5.  The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.

Authors:  G Høyer-Hansen; N Behrendt; M Ploug; K Danø; K T Preissner
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

6.  Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.

Authors:  S Huang; L New; Z Pan; J Han; G R Nemerow
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

7.  c-Src activation plays a role in endothelin-dependent hypertrophy of the cardiac myocyte.

Authors:  B Kovacic; D Ilić; C H Damsky; D G Gardner
Journal:  J Biol Chem       Date:  1998-12-25       Impact factor: 5.157

8.  Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes.

Authors:  Y Jiang; R Pannell; J N Liu; V Gurewich
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

9.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

10.  Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes.

Authors:  J Bohuslav; V Horejsí; C Hansmann; J Stöckl; U H Weidle; O Majdic; I Bartke; W Knapp; H Stockinger
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.